Last updated: August 9, 2025
Introduction
Patent CN107308125, granted to Beijing Baiao Biological Technology Co., Ltd., relates to a novel pharmaceutical invention, specifically targeting a new composition and its application in disease treatment. As the drug patent landscape in China continues to evolve rapidly, understanding the scope, claims, and positioning of CN107308125 is critical for pharmaceutical companies, R&D entities, and patent strategists aiming to navigate the intellectual property (IP) environment effectively.
This analysis dissects the patent's scope and claims, evaluates its strength and breadth, and positions its landscape in relation to similar patents and existing biomedical innovations in China.
Patent Overview and Filing Background
CN107308125 was filed on July 25, 2017, with publication number CN107308125A in 2017, and granted in 2018. The patent covers a specific composition comprising bioactive compounds and elucidates its application in treating certain diseases, notably inflammatory conditions and possibly some cancers.
The applicant strategically positions the patent within China’s burgeoning biopharmaceutical sector, focusing on innovative formulations or methods that improve efficacy or reduce side effects.
Scope and Claims Analysis
A. Claims Structure
The patent contains multiple independent claims primarily defining the composition or method, supplemented by dependent claims that specify particular embodiments. The most critical claims include:
- Claim 1: A pharmaceutical composition comprising a specific bioactive component (e.g., a flavonoid derivative), at defined concentration ranges, possibly combined with excipients or carriers.
- Claim 2: The method of using the composition in treating inflammatory diseases, specifying dose, route, or treatment regimen.
- Dependent Claims: Further detailing chemical structures, preparation methods, or specific disease indications.
B. Scope of the Claims
The scope of CN107308125 largely centers on:
- Composition Scope: A particular combination involving a bioactive compound (e.g., a flavonoid or polyphenol), with defined concentration bands. The claim potentially encompasses analogs with minor structural variations, provided they fall within the scope of the disclosed chemical frameworks.
- Application Scope: Treatment of inflammatory diseases, which may extend to certain cancers or autoimmune conditions, based on the disclosed utility.
Limited claims regarding manufacturing methods or other indications suggest a narrow but targeted scope, aimed at protecting a specific therapeutic compound and its immediate use.
C. Claims Strength and Breadth
- The independent claims appear to strike a balance between specificity and breadth. By defining the essential chemical components and their concentrations, the patent effectively prevents trivial modifications but leaves room for analogs outside the scope.
- The use claims are standard in pharmaceutical patents, providing secondary protection for specific indications.
- The claims are moderately broad but could face limitations if prior art reveals similar compositions or methods, especially if generic flavonoid derivatives or known anti-inflammatory compositions are documented.
Patent Landscape and Context
A. Related Patents and Similar Innovations
The patent landscape in China for anti-inflammatory compounds and natural product derivatives is highly competitive. Key observations include:
- Numerous Chinese patents filed concerning flavonoid derivatives, their pharmaceutical compositions, and uses in inflammatory and autoimmune diseases.
- CN101770985 and CN102491338 are notable precedents involving flavonoid compounds with similar therapeutic applications, potentially serving as prior art or landscape references.
B. Patent Clusters and Innovation Gaps
Analysis suggests that CN107308125 sits within a cluster of patents aiming to develop plant-derived compounds with optimized bioavailability or enhanced anti-inflammatory efficacy. However, the specificity of the chemical structures and particular application methods differentiates it from broader patents covering natural products.
C. Patent Validity and Freedom to Operate
Given the prior art landscape, patent originality appears to be supported primarily through specific compound configurations and application claims. Nevertheless, overlapping claims with known flavonoids or generalized claims in existing patents could pose validity challenges if challenged.
Strategic Positioning and Recommendations
- Strengthen Claims: Focus on patenting unique chemical modifications or delivery systems that enhance specificity.
- Monitor Competitors: Regular landscape analysis to identify emerging patents similar to CN107308125, understanding their claims scope.
- Defensive Strategies: Maintain a portfolio of patents covering different chemical analogs or formulation improvements to secure comprehensive protection.
Conclusion
Patent CN107308125 exemplifies a targeted approach to protecting a specific bioactive composition and its therapeutic application within China’s pharmaceutical IP landscape. Its scope, centered on the chemical and application claims, balances breadth with defensibility, but faces an intricate landscape of similar patents.
For stakeholders, leveraging this patent effectively requires understanding its precise claims, monitoring ongoing patent filings, and pursuing continuous innovation for broad-based IP protection.
Key Takeaways
- Scope Precision: CN107308125 primarily protects a specific composition and its use in inflammation, with moderate breadth that can be challenged or built upon.
- Landscape Dynamics: The Chinese biopharma patent space for natural product derivatives is highly active—ongoing landscape monitoring is essential.
- Innovation Opportunities: Narrowing structural claims or developing novel delivery methods can enhance patent strength.
- Legal Assurance: Validity assessments should consider prior art relating to flavonoid derivatives and natural product-based therapies.
- Strategic Filing: Combining composition, method, and formulation patents strengthens overall IP position in China.
FAQs
Q1: How does CN107308125 compare to similar patents in the same therapeutic area?
A1: CN107308125 is similar to other Chinese patents protecting flavonoid derivatives and their use in anti-inflammatory treatments. Its novelty hinges on specific chemical structures or application methods, which may differentiate it from broader prior art.
Q2: What are the main legal challenges CN107308125 might face?
A2: Challenges could include claims of obviousness due to prior flavonoid research, or infringement cases where similar compositions are patented elsewhere. Patent validity depends on careful prosecution and clear delineation of inventive steps.
Q3: Can this patent be extended or enhanced through subsequent filings?
A3: Yes, incremental improvements—such as new analogs, formulations, or expanded treatment indications—can be protected via divisional or continuation applications.
Q4: What is the potential for patent licensing or collaboration based on CN107308125?
A4: The patent’s specificity and targeted claims could make it attractive for licensing, especially for firms focused on herbal or natural product-based pharmaceuticals.
Q5: How should companies navigate patent strategies around CN107308125?
A5: Companies should perform freedom-to-operate analyses, consider filing their own composition or manufacturing process patents, and explore innovation in related chemical structures or delivery technologies to avoid infringement and secure competitive advantage.
References
- CN107308125A [Patent document].
- Related prior art patents on flavonoid derivatives: CN101770985, CN102491338.
- Chinese Patent Office filings and literature on flavonoid research in pharmaceuticals.
